Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 3, 2009, Pages 311-320

  Lowe, Frazer J ^a   Gregg, Evan O ^b   McEwan, Michael ^a  

^a BRITISH AMERICAN TOBACCO   (United Kingdom)

^b ENI Limited   (United Kingdom)

Author keywords

Biomarkers; Cardiovascular risk; Evaluation; Potential reduced exposure products; Smoking

Indexed keywords

11 OXOTHROMBOXANE B2; 3 DINORTHROMBOXANE B2; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 5,6 DIHYDRO 5,6 DIHYDROXYTHYMIDINE; 8 EPI PROSTAGLANDIN F 2ALPHA; 8 HYDROXYDEOXYGUANOSINE; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINE; PROSTAGLANDIN DERIVATIVE; THROMBOXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PASSIVE SMOKING; PRIORITY JOURNAL; SMOKING HABIT; URINALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DEOXYGUANOSINE; DINOPROST; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NICOTINE; NITROSAMINES; PYRIDINES; REPRODUCIBILITY OF RESULTS; SMOKE; SMOKING; SMOKING CESSATION; THROMBOXANE B2; THYMIDINE;

EID: 63849215165     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.069     Document Type: Article

References (51)

1. Baker RR. Smoke chemistry. In: Davis MT, Nelson DL, editors. Tobacco production, chemistry and technology. Oxford: Blackwell Science, 1999:398-440.
2. Green CR, Rodgman A. The Tobacco Chemists Research Conference: a half century forum for advances in analytical methodology of tobacco and its products. Rec Adv Tobacco Sci 1996;22:131-304.
3. ISO 3308. Routine analytical smoking machine - definition and standard conditions. Geneva: International Organisation for Standardisation, 2000.
4. Federal Trade Commission. Cigarettes. Testing for tar and nicotine content - statements for consideration. Federal Register 1967;32:11178.
5. Baker RR. The development and significance of standards for smoking machine methodology. Beitr Tabakforsch Int 2002;20:23-41.
6. Sutton SR, Russell MA, Iyer R, Feyerabend C, Saloojee Y. Relationship between cigarette yields, puffing patterns and smoke intake: evidence for tar compensation? Br Med J 1982;285:600-3.
7. World Health Organization. World health report 2002: reducing risks, promoting healthy life. Geneva: World Health Organisation, 2002.
8. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EM. Systemic effects of smoking. Chest 2007;131:1557-66.
9. Waller RE, Froggatt P. Product modification. Br Med Bull 1996;52:193-205.
10. Stratton K, Shetty P, Wallace R, Bondurant S, editors. Clearing the smoke. Assessing the science base for tobacco harm reduction. Washington DC: National Academy Press, 2001:636 pp.
11. WHO Scientific Advisory Committee on Tobacco Product Regulation. SACTob statement of principles guiding the evaluation of new or modified tobacco products. Geneva: World Health Organisation, 2003:12 pp.
12. Gregg EO, Fisher AL, Lowe F, McEwan M, Massey ED. An approach to the validation of biomarkers of harm for use in a tobacco context. Regul Toxicol Pharmacol 2006; 44:262-7.
13. Tricker AR. Biomarkers derived from nicotine and its metabolites: a review. Beitr Tabakforsch Int 2006;22: 147-75.
14. Hecht SS, Carmella SG, Chen M, Dor Koch JF, Miller AT, Murphy SE, et al. Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation. Cancer Res 1999;59:590-6.
15. Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis 1992;13:2241-7.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
17. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004;15 (Suppl 1):III2-7.
18. Peter K, Weirich U, Nordt TK, Ruef J, Bode C. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis. Thromb Haemost 1999;82 (Suppl 1):38-43.
19. Gimbrone MA Jr. Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am J Cardiol 1995;75:67B-70.
20. Spronk HM, van der Voort D, Ten Cate H. Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb J 2004;2:12.
21. Collinson PO, Gaze DC. Biomarkers of cardiovascular damage. Med Princ Pract 2007;16:247-61.
22. Ni CY. Cardiac troponin I: a biomarker for detection and risk stratification of minor myocardial damage. Clin Lab 2001;47:483-92.
23. Stone PJ, Gottlieb DJ, O'Connor GT, Ciccolella DE, Breuer R, Bryan-Rhadfi J, et al. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;151:952-9.
24. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 2005;10(Suppl 1):S10-23.
25. Xia Y, McGuffey JE, Bhattacharyya S, Sellergren B, Yilmaz E, Wang L, et al. Analysis of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol in urine by extraction on a molecularly imprinted polymer column and liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Anal Chem 2005;77:7639-45.
26. Pan J, Song Q, Shi H, King M, Junga H, Zhou S, et al. Development, validation and transfer of a hydrophilic interaction liquid chromatography/ tandem mass spectrometric method for the analysis of the tobacco-specific nitrosamine metabolite NNAL in human plasma at low picogram per milliliter concentrations. Rapid Commun Mass Spectrom 2004;18:2549-57.
27. St. Charles FK, Krautter GR, Dixon M, Mariner DC. A comparison of nicotine dose estimates in smokers between filter analysis, salivary cotinine, and urinary excretion of nicotine metabolites. Psychopharmacology 2006;189:345-54.
28. Tricker AR. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour. Toxicology 2003;183:151-73.
29. Lyons MA, Yang RS, Mayeno AN, Reisfeld B. Computational toxicology of chloroform: reverse dosimetry using Bayesian inference, Markov chain Monte Carlo simulation, and human biomonitoring data. Environ Health Perspect 2008;116:1040-6.
30. Pelkonen O, Kapitulnik J, Gundert-Remy U, Boobis AR,Stockis A. Local kinetics and dynamics of xenobiotics. Crit Rev Toxicol 2008;38:697-720.
31. Zedler BK, Kinser R, Oey J, Nelson B, Roethig HJ, Walk RA, et al. Biomarkers of exposure and potential harm in adult smokers of 3-7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers 2006;11:201-20.
32. Rangemark C, Wennmalm A. Cigarette smoking and urinary excretion of markers for platelet/vessel wall interaction in healthy women. Clin Sci 1991;81:11-5.
33. Wennmalm A, Benthin G, Granstrom EF, Persson L, Winell S. Maintained hyperexcretion of thromboxane A2 metabolite in healthy young cigarette smokers: results from a prospective study in randomly sampled males with stable smoking habits. Clin Physiol 1993;13:257-64.
34. Uedelhoven WM, Rutzel A, Meese CO, Weber PC. Smoking alters thromboxane metabolism in man. Biochim Biophys Acta 1991;1081:197-201.
35. Dotevall A, Rangemark C, Eriksson E, Kutti J, Wadenvik H, Wennmalm A. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. Thromb Haemost 1992;68: 583-8.
36. Rangemark C, Benthin G, Granstrom EF, Persson L, Winell S, Wennmalm A. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. Circulation 1992;86:1495-500.
37. Al-Ghamdi HS, Anil S. Serum antibody levels in smoker and non-smoker Saudi subjects with chronic periodontitis. J Periodontol 2007;78:1043-50.
38. Tollerud DJ, Brown LM, Blattner WA,Weiss ST, Maloney EM, Kurman CC, et al. Racial differences in serum immunoglobulin levels: relationship to cigarette smoking, Tcell subsets, and soluble interleukin-2 receptors. J Clin Lab Anal 1995;9:37-41.
39. Hersey P, Prendergast D, Edwards A. Effects of cigarette smoking on the immune system. Follow-up studies innormal subjects after cessation of smoking. Med J Aust 1983;2:425-9.
40. Keaney JF, Larson MG, Vasan RS, Wilson PF, Lipinska I,Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003;23:434-9.
41. Harman SM, Liang L, Tsitouras PD, Gucciardo F, Heward CB, Reaven PD, et al. Urinary excretion of three nucleic acid oxidation adducts and isoprostane F(2)alpha measured by liquid chromatography-mass spectrometry in smokers, ex-smokers, and nonsmokers. Free Radic Biol Med 2003;35:1301-9.
42. Loft S, Fischer-Nielsen A, Jeding IB, Vistisen K, PoulsenHE. 8-hydroxydeoxyguanosine as a urinary biomarker of oxidative DNA damage. J Toxicol Environ Health 1993; 40:391-404.
43. Chuang CY, Lee CC, Chang YK, Sung FC. Oxidative DNAdamage estimated by urinary 8-hydroxydeoxyguanosine: influence of taxi driving, smoking and areca chewing. Chemosphere 2003;52:1163-71.
44. Barcin C, Tapan S, Kursaklioglu H, Iyisoy A, Olcay A, Erbil MK, et al. Effects of non-heavy smoking on highdensity lipoprotein cholesterol in healthy Turkish young men. Acta Cardiol 2006;61:411-5.
45. Sharma SB, Dwivedi S, Prabhu KM, Singh G, Kumar N,Lal MK. Coronary risk variables in young asymptomatic smokers. Indian J Med Res 2005;122:205-10.
46. Haarbo J, Hassager C, Schlemmer A, Christiansen C. Influence of smoking, body fat distribution, and alcohol consumption on serum lipids, lipoproteins, and apolipoproteins in early postmenopausal women. Atherosclerosis 1990;84:239-44.
47. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
48. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. J Am Coll Cardiol 2007;49:2129-38.
49. Wallace KB, Hausner E, Herman E, Holt GD, MacGregor JT, Metz AL, et al. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004;32: 106-21.
50. Hoffmann H, Isner C, Högel J, Speit G. Genetic polymorphismsand the effect of cigarette smoking in the comet assay. Mutagenesis 2005;20:359-64.
51. Han S, Zhang HT, Wang Z, Xie Y, Tang R, Mao Y, et al. DNA repair gene XRCC3 polymorphisms and cancer risk: a meta-analysis of 48 case-control studies. Eur J Hum Genet 2006;14:136-44.